Field Medical has announced the appointment of Mark Turco as chief executive officer (CEO), effective immediately.
As per a Field Medical press release, Turco brings more than 30 years of leadership experience spanning venture-backed cardiovascular startups and executive roles within large-cap medical device organisations. He has led multiple clinical-stage companies through development and strategic transactions, building organisations positioned for long-term scale.
“Mark’s unique background as a cardiologist, clinical triallist and an experienced medical device executive equips him well to guide Field Medical through this next phase of growth,” said Ben Cannon, board member of Field Medical, and member of the BioStar Capital and Cue Growth investment teams. “As we accelerate our clinical programmes and strengthen our operational capabilities, his executive experience in advancing complex medical technologies across development, regulatory and commercialisation milestones will enable disciplined execution and sustainable long-term value creation.”
Turco previously served as president and CEO of JC Medical, where he led development of a dedicated transcatheter aortic valve replacement (TAVR) system for aortic regurgitation that was acquired by Edwards Lifesciences in July 2024. Prior to that, he held senior leadership roles at Medtronic and Covidien, serving as vice president and chief medical officer of the vascular and neurovascular franchises, and most recently served as president and CEO of the Rhode Island Life Science Hub. A board-certified interventional cardiologist prior to transitioning into industry, Turco brings both clinical insight and operational experience to the leadership of Field Medical.
“I am honoured to join Field Medical at this pivotal moment in its evolution,” Turco commented. “The company has built a differentiated PFA [pulsed field ablation] platform with the potential to meaningfully address significant unmet patient needs in both ventricular arrhythmias and atrial fibrillation. I look forward to partnering closely with the exceptional Field Medical team to rigorously advance our clinical programmes and navigate regulatory pathways to meet our operational goals.”
Field Medical is a clinical-stage medical technology company advancing second-generation PFA solutions intended for the treatment of complex ventricular and atrial cardiac arrhythmias. Its FieldForce ablation system was accepted into the US Food and Drug Administration (FDA)’s Total Product Life Cycle Advisory Program (TAP) pilot and granted breakthrough device designation for sustained monomorphic scar-related ventricular tachycardia (VT) in 2024—but, according to the company, currently remains an investigational device that is limited by US federal law to investigational use.
